Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user is considering switching to oral dutasteride, topical minoxidil, retinoic acid, and clobetasol for hair loss treatment, after limited regrowth with finasteride and other topicals. They are seeking a source for clobetasol, as they believe it may help with their condition.

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

The user is experiencing hair loss and confusion over conflicting medical advice, with treatments including minoxidil, finasteride, and topical corticosteroids. They are unsure about the necessity of a biopsy and the timing of using minoxidil, while also considering the impact of potential androgenetic alopecia and telogen effluvium.

High-dose Dutasteride slightly reduces scalp itch, but adding RU58841 eliminates it completely. Some users report reduced itchiness and oiliness with Dutasteride, while others find topical anti-androgens more effective.

Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

Controlling insulin levels through intermittent fasting and a low glycemic diet may improve hair quality by reducing androgens. It's important to maintain proper nutrition, including electrolytes and protein, during fasting.

A user is experiencing ongoing hair loss despite using 0.5mg dutasteride and 2.5mg oral minoxidil for several years and is seeking advice. Suggestions include ensuring correct diagnosis, checking for other health issues, considering finasteride, trying topical antiandrogens, and consulting a dermatologist.

A 15-year-old is upset about androgenic alopecia and its effect on self-esteem. Recommendations include minoxidil, microneedling, hair systems, and focusing on self-confidence and therapy.

The user stopped oral treatments due to side effects and switched to a regimen of topical minoxidil, tretinoin, azelaic acid, and dermaneedling, with recent addition of topical finasteride. They are questioning the long-term effectiveness of non-hormonal methods and considering hair transplantation.

Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.

The conversation discusses hair loss treatment options, focusing on finasteride and its potential effects on gynecomastia. The user is considering finasteride while managing hormone levels with supplements like boron, vitamin D, zinc, magnesium, and P5P, and is advised to consult an endocrinologist for further evaluation.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

A 22-year-old male uses dutasteride, a serum with 10% minoxidil and 0.5% finasteride, and microneedling for diffuse androgenetic alopecia. Progress pictures show changes from July 2025 to February 2026.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

The user experienced hair loss due to androgenic alopecia and chose to use essential oils (rosemary and peppermint) and microneedling instead of minoxidil or finasteride. They reported positive results after 24 days and plan to continue with these treatments.

The user saw significant hair regrowth using topical minoxidil and finasteride, even on areas not directly treated. They used local Algerian products with 5% minoxidil and 0.1% finasteride and reported no side effects.

RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.

A user experienced accelerated hairline recession after adding dutasteride to their regimen of topical finasteride and minoxidil, despite reduced hair shedding. They were informed that ELISA testing for DHT levels can be highly inaccurate.

The conversation discusses an experiment involving hair loss treatments, including the use of Verteporfin, KY19382, dutasteride, oral and topical minoxidil, AHK-Cu, and microneedling. The experiment aims to test the effectiveness of these treatments in promoting hair growth and healing without scarring, with updates planned every few months.

A 25-year-old discusses using castor oil combined with minoxidil for alopecia areata after noticing hair loss. They seek advice on the effectiveness of this treatment.

High-dose Lysine and Histidine supplements caused curly/kinky hair and shedding due to Elastin dysfunction. Minoxidil, white tea, and dark grape juice were mentioned as treatments to inhibit Elastase and mimic Lysyl Oxidase.

Using 1.5mg dutasteride, 2.5mg oral minoxidil, and topical RU58841 may help manage hair loss while on testosterone, but regrowth is uncertain. Users report varying success with different dosages and combinations of these treatments.

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

The conversation discusses attending a presentation by Pelage at the Academy of Dermatology Annual Meeting in Denver, focusing on hair loss treatments. Participants express interest in obtaining information or trial compounds related to hair loss solutions like Minoxidil, finasteride, and RU58841.

A user discusses using dermastamping for hair loss and questions the timing of applying a mixture of peppermint oil, spearmint oil, rosemary oil, and castor oil due to their anti-inflammatory effects. They wonder if waiting 10 hours after stamping would be more effective.

The user is experiencing scalp irritation from using RU58841 with a 70% ethanol and 30% propylene glycol vehicle and is considering switching to a less irritating vehicle, such as 30% ethanol with 70% squalane or emu oil. They are seeking feedback on the effectiveness and irritation levels of these alternative carriers.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

The conversation discusses skepticism about a new hair loss treatment called project K, which claims to replicate a chemical from UCLA research but is suspected to be a scam. The original poster plans to continue using oral minoxidil, finasteride, and dutasteride, along with microneedling, for hair regrowth.